Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (32): 6073-6076.doi: 10.3969/j.issn.1673-8225.2010.32.041

Previous Articles    

Haploidentical hematopoietic stem cells transplantation for the treatment of medulloblastoma

Hu Hai-yan, Guo Hong-bo, Wu Bing-yi, Deng Lan, Song Chao-yang, Guo Kun-yuan   

  1. Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou  510282, Guangdong Province, China
  • Online:2010-08-06 Published:2010-08-06
  • Contact: Guo Kun-yuan, Associate professor, Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China
  • About author:Hu Hai-yan☆, Doctor, Associate investigator, Department of, Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China xuri1104@163.com
  • Supported by:

    the National Natural Science Foundation of China, No. 30800486*

Abstract:

BACKGROUND: Some reports demonstrated that, autoallergic or hematopoietic stem cells transplantation combined with chemotherapy received good outcomes in treating medulloblastoma, which can prolong survival time of patients. However, whether haploidentical hematopoietic stem cells transplantation can treat medulloblastoma remains poorly understood.
OBJECTIVE: To firstly report a patient receiving haploidentical hematopoietic stem cells transplantation for treating medulloblastoma.
METHODS: A terminal cancer patient with bone matastases successively received six lymphocyte transfusions from an unrelated donor combined with chemotherapy and three haploidentical hematopoietic stem cell transplantations.
RESULTS AND CONCLUSION: The patient presented erythra, accompanied by fever, diarrhea and yellow brown liquid stools, which was considered as graft versus host disease, and treated by urbason, gammaglobulin, CellCept, Prograf, Basiliximab (anti-CD25 antibody), Infliximab (anti-tumor necrosis factor α antibody), effective antibacterial and supportive treatments. After that, the erythra and diarrhea were remised. But the patient died from cerebral hemorrhage. Allogeneic lymphocyte transfusion can kill or damage tumor cells, improve life quality, but the outcome is restrained for patient with a high tumor burden. Immunosuppressant, such as anti-CD25 antibody and anti-tumor necrosis factor α antibody should be timely used in consideration of allogeneic hematopoietic stem cell transplantation.

CLC Number: